Avidity Partners Management’s Compass Therapeutics CMPX Stock Holding History

Avidity Partners Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,599,600	Closed	-$2.5M	–	98
2023 Q4	$2.5M	Hold	1,599,600	–	–	0.09%	69
2023 Q3	$3.15M	Sell	1,599,600 -20,600	-1%	-$50.9K	0.13%	77
2023 Q2	$5.15M	Sell	1,620,200 -204,800	-11%	-$643K	0.18%	81
2023 Q1	$5.97M	Sell	1,825,000 -175,000	-9%	-$687K	0.2%	70
2022 Q4	$10.1M	Hold	2,000,000	–	–	0.22%	60
2022 Q3	$4.56M	Hold	2,000,000	–	–	0.09%	81
2022 Q2	$5.3M	Hold	2,000,000	–	–	0.12%	58
2022 Q1	$2.74M	Hold	2,000,000	–	–	0.06%	83
2021 Q4	$6.34M	Buy	+2,000,000	New	+$6.63M	0.13%	73

Other funds holding CMPX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Avidity Partners Management's CMPX Position: Q1 2024 in Review

Avidity Partners Management sold out of Compass Therapeutics (CMPX) in Q1 2024, closing a stake of 1,599,600 shares — an estimated $2.5M sold.

Avidity Partners Management first reported a position in CMPX in Q4 2021 and held it in 9 quarters. The position peaked at $10.1M in Q4 2022. 78 funds tracked by Wall St. Rank hold CMPX as of Q1 2024.

Avidity Partners Management reported no remaining Compass Therapeutics position as of Q1 2024 after selling out during the quarter.
Avidity Partners Management sold 1,599,600 Compass Therapeutics shares in Q1 2024, an estimated $2.5M.
Avidity Partners Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 9 quarters.
Avidity Partners Management's Compass Therapeutics position peaked at $10.1M in Q4 2022.
78 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2024.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.